updated 6/22/2011 7:16:47 AM ET 2011-06-22T11:16:47

DALLAS, June 22, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces a stock review of PharmAthene Inc. (AMEX:PIP). The report includes the company's most recent developments, including its ongoing lawsuit, as well as technical trends, financial analysis, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/lp/PIP

PharmAthene Inc. (PIP) is a biodefense company engaged in the development and commercialization of medical countermeasures against biological and chemical weapons. The Company's lead product development programs include: SparVax, a second generation recombinant protective antigen (rPA) anthrax vaccine and a third generation anthrax vaccine with potential for improved potency and stability; Valortim, a fully human monoclonal antibody for the prevention and treatment of anthrax infection; and rBChE, which countermeasures for nerve agent poisoning by organophosphorous compounds, including nerve gases and pesticides.

This newsletter has been helping traders make great investment decisions on PIP; click here for a 25% discount offer.

In the report, the analyst notes:

"Shares of the biodefense company spiked more than 26% in Tuesday's trading, a day after the Company was highlighted in a SeekingAlpha report, which suggests that a lawsuit it is involved in with Siga Technologies will likely be ruled in its favor."

"In the past 52 weeks, PIP has traded between a low of $1.26 and a high of $4.96. Approximately 2.65 million shares have traded hands during the session, versus the average daily volume of 1.01 million. PIP remains below its 50-day and 200-day moving averages of $3.54 and $3.46, respectively."

To read the entire report visit: www.microstockprofit.com/lp/PIP

See what investors are saying about PIP at http://www.stockhideout.com

Get breaking news on PIP at http://thestockmarketwatch.com/

MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

CONTACT: Jay Geller

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com